DNDi aims to deliver:

  • A safe, effective, and easy-to-use direct-acting antiviral regimen, to be used as an affordable combination paving the way for a public health approach to HCV.
  • Increased access to affordable treatments by supporting policy change and encouraging political will to treat HCV.
  • Innovative programmes to improve access to HCV diagnosis and treatment in a variety of countries.

 

The current hepatitis C portfolio includes:

Development

Development

Ravidasvir / Sofosbuvir
Ravidasvir

 

For more details on each project, see DNDi‘s Global Portfolio

 

 

More information:

A Public Health Approach to the Hepatitis C Epidemic
Extending the DAA treatment revolution to neglected patients